相关临床试验
4
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1951
进行中（未招募）
3
75.0%
已完成
1
25.0%
暂无批准数据
- The Aikenhead Centre for Medical Discovery (ACMD), Australia's first hospital-based biomedical engineering research centre, has opened at St Vincent's Hospital in Fitzroy, Melbourne. - The AU$206 million facility brings together clinicians, scientists, and engineers to fast-track medical discoveries into patient benefits using AI, biotechnology, and regenerative medicine. - The centre can accommodate up to 900 researchers, train 300 new doctors annually, and features 3D printing labs, a kinetics lab, engineering workshops, and robotics. - Research will target chronic conditions including epilepsy, cancer, and osteoarthritis, with the goal of translating laboratory discoveries to the bedside faster and more reliably.
- Victorian researchers at St Vincent's Institute of Medical Research have developed a groundbreaking RNA-based treatment using Prime Editing technology to correct genetic defects causing Fanconi anemia and other life-threatening blood disorders. - The innovative therapy offers a safer alternative to risky bone marrow transplants for treating rare childhood diseases that affect approximately 190 young Australians annually. - The treatment is progressing through safety studies with plans for a world-first clinical trial, supported by $100,000 in government funding and partnerships with patient advocacy organizations.
- Phase 2 BANDIT trial demonstrates Eli Lilly's Olumiant (baricitinib) can slow progression of type 1 diabetes by preserving insulin-producing beta cell function over 48 weeks of treatment. - Patients receiving Olumiant required significantly less insulin therapy and experienced decreased blood glucose fluctuations compared to placebo, potentially reducing treatment burden. - Researchers identify TYK2 inhibition as another promising approach for type 1 diabetes treatment, with an FDA-approved psoriasis drug potentially offering a dual mechanism to protect beta cells and reduce inflammation.
